Stem cells have huge potential to transform current manner in which medicine is practiced. Rather than treating diseased cells with medicines and antibiotics, stem cells can just replace the diseased cells with healthy cells. But it will take time before this research gets translated to the clinic. At present, various types of stem cells like human embryonic stem (hES) cells, induced pluripotent stem (iPS) cells, fetal stem cells, adult tissue-specific stem cells (HSCs, MSCs, etc.), very small embryonic-like stem cells (VSELs) and related technologies like therapeutic cloning are subject to extensive research. Clinicians appear to be in a hurry to apply the stem cells to their patients and there is a huge industry banking stem cells for future autologus use. However, the scientific community is still not sure which is the best stem cell candidate for regenerative medicine. The chapter provides an update on various fronts and also discusses whether there exists a need to bank stem cells for future use. The author is puzzled by realizing as to what needs to be repaired/ regenerated-the stem cells or their microenvironment 'niche'!
INTRODUCTION
Potential of stem cells to regenerate diseased organs has raised hopes of many. Of all the stem cells, human embryonic stem (hES) cells, reported for the first time by Thomson' s group 46 have maximum regenerative potential as they are pluripotent in nature and can give rise to all the three germ layers and 200 hundred odd cell types in the body. However, these stem cells have two major associated con cerns including (i) immune rejection after cell therapy and (ii) risk of teratoma formation. Embryonic stem cells are derived from the inner cell mass of spare human blastocyst, express HLA antigens when they differentiate into various committed cell types and hence face the issue of immune rejection.
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This immune rejection issue can be overcome by either making patient specific stem cells by cloning or by repro gramming adult somatic cells to embryonic state by using 'Yamanaka factors'. 45 The later approach results in the expansion of induced pluripotent stem (iPS) cells and this technology developed by Prof Shinya Yamanaka was awarded Nobel Prize in Medicine in 2012. Indeed this award was shared with Prof JB Gurdon who had reported 40 years earlier that on replacing the nucleus of a frog egg by a mature cell from the intestine resulted in the development of a normal tadpole. 9 Thus, he showed for the first time that oocyte cytoplasm had factors that could reprogram a somatic cell to embryonic state. This process of reproductive cloning resulted in the birth of first mammal-Dolly, the sheep in 1996 at the Roslin Institute in Scotland after 227 attempts. An udder cell from a 6yearold sheep was injected in an enucleated unfertilized egg and later transplanted in utero resulted in the birth of Dolly which also produced a normal offspring. However, Dolly had to be euthanized at the age of six and half (against a normal age of 1112 years), because she developed arthritis in her hind leg and lung tumor-both being diseases which manifest with age. Her chromosomal telomeres were also shorter than other sheep of her age. All this implied that she aged early as she was formed from an udder cell of a 6-year-old sheep. A modification of repro ductive cloning (which is not permitted in humans) is therapeutic cloning whereby a somatic cell can be injected in an enucleated egg to produce a blastocyst which can then serve as a source of inner cell mass to grow embryonic stem cells (Fig. 1 ). These ES cells will be patient specific and immune rejection could be overcome. This technology is also termed somatic cell nuclear transfer and falls under the category of restricted area of research based on the SCNT, but they are a scarce commodity and using human eggs for SCNT is an extremely sensitive ethical issue, especially after the Hwang episode in Korea. 6 A project to establish patient specific ES cell lines by SCNT has been submitted by us for various approvals, however, it has been more than 6 to 7 years but the study has not yet been initiated. Meanwhile, our research efforts have identified a novel population of pluripotent stem cells in adult body tissues termed very small embryoniclike stem cells (VSELs). The existence and potential of VSELs make the need to carry out SCNT unnecessary and we also contemplate that when pluripotent stem cells exist in adult body tissues-what is the need of pluripotent ES/iPS cells grown in a Petri dish for regenerative medicine. This chapter provides a broad overview on the advances made using these different kinds of stem cells and related technologies.
CURRENT STATUS OF SCNT
Somatic cell nuclear transfer was described as the method of the year 2013 when Prof Mitalipov from Oregon pub lished the derivation of human ES cell lines by SCNT. 44 It was the most discussed study of 2013 and the efficiency was described as one egg donation cycle will give rise to 8 mature oocytes and hopefully 4 cell lines. The group reported several genetic abnormalities in iPS cells but not in cell lines derived by SCNT. 19, 32 He mentioned that it took 6 years to overcome regulatory hurdles but only 3 months to do the work. Future of the technology depends on the policymakers and how various countries regulate egg donors and make them available for research. 
CURRENT STATUS OF ES AND IPS CELLS RESEARCH AND THERAPY

INTRODUCTION TO VERY SMALL EMBRYONIC-LIKE STEM CELLS (VSELs)
Besides ES and iPS cells, another type of pluripotent stem cell were the embryonic germ cells reported by Shamblott's group 40 and derived from migrating primordial germ cells (PGCs). These stem cells are pluripotent just like ES cells but do not expand in culture as well. 47 The PGCs migrate along the dorsal mesentery, settle in the gonadal ridge and differentiate into germ cells. Recent literature shows that the PGCs in addition to settling in the gonadal ridge-also migrate an settle in various developing organs-sit on the top of hierarchy of all tissue-specific adult stem cells in the body and survive throughout life as VSELs which act as a backup pool for the adult tissue specific stem cells. These stem cells were described for the first time by Professor Ratajczak's group at the University of Louisville, USA. 15, 35 Very small embryoniclike stem cells are very small in size, easily discarded during volume reduction step during processing of cord blood, bone marrow and various other tissues.
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Very small embryoniclike stem cells have been proposed to be similar to late migrating PGCs. 41 Similar to hES cells, VSELs are pluripotent however may prove to be better than human ES/iPS cells in a clinic, because (i) they can be isolated from autologus source and thus immune rejection issues do not exist and (ii) they do not form teratoma. There is no comparison of VSELs with adult stem cells, since it is becoming apparent that indeed VSELs give rise to various adult stem cells. Very small embryoniclike stem cells are easily mobilized in case of injury. 16, 23, 33, 50 We have published extensively on VSELs in the gonads. 4 Whatever autologus stem cell trials that have been conducted worldwide till date, VSELs have been invariably discarded during processing. Thus, an urgent need exists to undertake clinical studies with these stem cells. The therapy will be absolutely safe, since they will be from an autologus source, but hopefully the efficacy will be higher.
Thus, it is time for stem cell biologists to sit and retros pect. There is a need to brain storm how to move forward in the field of regenerative medicine. Is it necessary to play with emotions of a common man and invite them to bank their teeth stem cells, menstrual blood stem cells, cord blood stem cells etc? Ultimately it is the VSELs that will make all the difference and whatever the source -it is this stem cell that needs to be exploited. Whenever required, they can be easily isolated from the patients' adipose tissue, bone marrow or any other organ. I personally do not see any scope of banking stem cells! One problematic issue of major cancer is that VSELs exist in very few numbers and they do not expand in culture-then how will they be useful for regeneration. We need to realize that VSELs give rise to progenitors which undergo clonal expansion in large numbers to maintain homeo stasis. Thus, very few VSELs are enough for a large number of progenitors. The million dollar question remains as to how we could exploit the VSELs for regenerative medi cine and also that despite their natural mobilizationwhy regeneration does not occur! These are mind boggling questions and we are coming to realize that rather than stem cells-it is the niche which is more crucial and gets compromized with age. If the scientists could repair the niche, stem cell biology will be normalized and regeneration will occur. Our group has reported VSELs in adult human testes, 2 adult mammalian ovaries, 2427 bone marrow and cord blood. 3 Recently, we have shown that VSELs are capable of regenerating adult mouse pancreas after partial pancreatectomy. 5 We also reported that VSELs survive in the testis 1 as well as in the ovary 41, 42 after chemotherapy. Further, we were able to restore testicular func tion by reconstructing the niche. 1 It is believed that VSELs could be the possible embryonic remnants existing in various adult body organs responsible for various cancers.
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To conclude stem cell biology field although having great clinical relevance, is still in infancy and lot more basic research is required and also brainstorming to decide on which stem cells to use and how for achieving regeneration.
